Abstract
Crystallographic structures of wild-type and mutant NOS isoforms complexed with substrate, intermediate, inhibitor, cofactor, and cofactor analogs are currently available. However, because of the high level of amino-acid conservation and the consequent similarity in dimeric quaternary structure as well as in the active site of NOS isoforms, structure-based isoform-selective inhibitor design is still a very challenging task. Nevertheless, the comprehension of the structural determinants for selectivity among the isoforms is fundamental for the design of further potent and more selective inhibitors. Computational techniques, based on the knowledge of the tridimensional structure of the isozymes, have been already applied to understand the significant isoform selectivity shown by some compounds. Collectively these structure-based approaches, in combination with SAR studies, have been able to explain the structural reasons of this selectivity.
Keywords: Drug design, NOS inhibitors, selective, modeling, computational
Current Medicinal Chemistry
Title: Computational Studies of Competitive Inhibitors of Nitric Oxide Synthase (NOS) Enzymes: Towards the Development of Powerful and Isoform-Selective Inhibitors
Volume: 13 Issue: 16
Author(s): A. Tafi, L. Angeli, G. Venturini, M. Travagli, F. Corelli and M. Botta
Affiliation:
Keywords: Drug design, NOS inhibitors, selective, modeling, computational
Abstract: Crystallographic structures of wild-type and mutant NOS isoforms complexed with substrate, intermediate, inhibitor, cofactor, and cofactor analogs are currently available. However, because of the high level of amino-acid conservation and the consequent similarity in dimeric quaternary structure as well as in the active site of NOS isoforms, structure-based isoform-selective inhibitor design is still a very challenging task. Nevertheless, the comprehension of the structural determinants for selectivity among the isoforms is fundamental for the design of further potent and more selective inhibitors. Computational techniques, based on the knowledge of the tridimensional structure of the isozymes, have been already applied to understand the significant isoform selectivity shown by some compounds. Collectively these structure-based approaches, in combination with SAR studies, have been able to explain the structural reasons of this selectivity.
Export Options
About this article
Cite this article as:
Tafi A., Angeli L., Venturini G., Travagli M., Corelli F. and Botta M., Computational Studies of Competitive Inhibitors of Nitric Oxide Synthase (NOS) Enzymes: Towards the Development of Powerful and Isoform-Selective Inhibitors, Current Medicinal Chemistry 2006; 13 (16) . https://dx.doi.org/10.2174/092986706777585031
DOI https://dx.doi.org/10.2174/092986706777585031 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Biochemical Markers of Renal Function
Current Medicinal Chemistry Transformation of UPLC-MS Data Overcomes Extreme Variability in Urine Concentration and Metabolite Fold Change
Current Metabolomics Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Cardiac Complications Attributed to Hydroxychloroquine: A Systematic Review of the Literature Pre-COVID-19
Current Cardiology Reviews HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
Current Cancer Drug Targets Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based Nanosystems)
Recent Patents on Anti-Cancer Drug Discovery Role of Central and Peripheral Chemoreceptors in Vasopressin Secretion Control
Endocrine, Metabolic & Immune Disorders - Drug Targets Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Animal Models for Parkinson's Disease
CNS & Neurological Disorders - Drug Targets The Main Receptors Involved in the COVID-19: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Current Vascular Pharmacology Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews CYP-Mediated Clozapine Interactions: How Predictable Are They?
Current Drug Metabolism The Optimal Treatment of Severe Hypertension in Pregnancy: Update of the Role of Nicardipine
Current Pharmaceutical Biotechnology Rabbit Models of Ocular Diseases: New Relevance for Classical Approaches
CNS & Neurological Disorders - Drug Targets Trends in Snakebite Envenomation Therapy: Scientific, Technological and Public Health Considerations
Current Pharmaceutical Design